GSK’s combination brings together Fluticasone ... to Ultibro Breezhaler from their previous therapy (LABA+ICS * or LABA or LAMA) experienced superior improvements in lung function (trough ...

Novartis has moved a step closer to EU approval of its three-drug asthma therapy Enerzair Breezhaler, and now looks set to beat a rival therapy from GlaxoSmithKline to market. Enerzair (formerly ...

Medscape UK, October 26, 2020 Triple Therapy (LABA/LAMA/ICS) vs LABA/LAMA Combo for COPD In patients with chronic obstructive pulmonary disease (COPD), triple therapy (long-acting beta ...

Respiratory nurse lead Carol Stonham outlines what nurses in primary care need to know about changes in the diagnosis and ...

Asthma–chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS) is a commonly encountered yet loosely defined clinical entity. ACOS accounts for approximately 15–25% of the ...

Click to share on Twitter (Opens in new window) Click to share on Facebook (Opens in new window) Click to share on LinkedIn (Opens in new window) Click to share on Telegram (Opens in new window) Click ...

Part two of this series sees Ravijyot Saggu explore pharmacological management recommendations from the new joint chronic ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

StockNews.com lowered shares of Innoviva (NASDAQ:INVA – Free Report) from a buy rating to a hold rating in a report published on Thursday. Innoviva Price Performance Shares of INVA opened at $18.08 on ...

By Ali Watkins Gyalo Thondup, the eldest brother of the Dalai Lama and a political operator ... to serve the Tibetan administration that is a combination of spirituality and politics once more.” ...